Follow on Google News News By Tag * Medical * Pharmaceutical * Devices * Equipment * Per-capita * Medicine * Conditions * Ghanaian * Healthcare * More Tags... Industry News News By Place Country(s) Industry News
Follow on Google News | New Market Study Published: Ghana Pharmaceuticals & Healthcare Report Q1 2011New Healthcare market report from Business Monitor International: "Ghana Pharmaceuticals & Healthcare Report Q1 2011"
In 2009 total pharmaceutical sales were GSH456mn (US$319mn). Market share is split quite evenly between patented drugs, generic drugs and over-the-counter (OTC) medicines, but due to the levels of wealth inequality across the population, pharmaceutical demand is predominantly influenced by drug pricing. Although, many pharmacists continue to purchase medicines from more expensive private sources, as foreign medications continue to be regarded as superior. In November 2010, Ghana reviewed its IP laws and put forward a motion to bring them into alignment with international standards. The West African country has previously had an inadequate IP regime, which not only failed to protect the IP of foreign drugmakers, but also made counterfeit medicines harder to regulate. This development will encourage more foreign direct investment (FDI), but will probably not have an impact before late 2011 - early 2012. After the discovery and development of an oil industry in Ghana, large proportion of the revenues of the hydrocarbon industry will go to paying off a US$13bn loan and trade agreement with China, which was signed in September 2010. Personal wealth will increase, as a result of employment creation from infrastructure projects, paid for by the Chinese loan. This will correlate to a higher per capita expenditure on healthcare and pharmaceuticals. However, a possible consequence of this development is rapidly increasing inflation, which would damage the profitability of investments. The National Health Insurance Scheme (NHIS) continues to increase in size and popularity, but there are fears that at its current rate of expansion, funding will become unsustainable by 2013 and the government may need to raise the NHIS value-added- In Q410, the FDB gave regulatory permission for Bafna Pharmaceuticals' to market atenolol and metformin in Ghana. BMI believes that the continued success of Indian generic drugmakers in Ghana will continue in the short term, however, we expect the government to begin to put more pressure on companies like Bafna to begin partnerships with local drugmakers. For more information or to purchase this report, go to: - http://www.fastmr.com/ Report Table of Contents: Executive Summary SWOT Analysis - Ghana Pharmaceutical and healthcare SWOT - Ghana Political SWOT - Ghana Economic SWOT - Ghana Business Environment SWOT Pharmaceutical Business Environment Ratings - Table: Middle East And Africa (MEA) - Regional Pharmaceutical Business Environment Ratings, Q410 - Rewards - Risks Ghana - Market Summary Regulatory Regime - Intellectual Property Regime - Counterfeit Medicines - Table: mPedigree's Activities In Ghana - Low-Cost Detection And Interception Technology - Pricing And Reimbursement Regimes - Rational Drug Prescribing Industry Developments - Epidemiology - Communicable Diseases - Non-Communicable Diseases - Healthcare Sector - Hospital Sector - Recent Healthcare Sector Developments - Health Insurance Sector - Telemedicine - Clinical Trials Sector - Medical Devices Sector Industry Forecast Scenario - Overall Pharmaceutical Market Forecast - Table: Pharmaceutical Sales Indicators 2006-2014 - Key Growth Factors - Industry - Table: Healthcare Expenditure Trends, Historical Data and Forecasts, 2006-2014 - Table: Healthcare Expenditure Trends, Historical Data and Forecasts, 2006-2014 - Key Growth Factors - Macroeconomic Outlook - Table: Ghana - Economic Activity - Pharmaceutical Trade Forecast - Table: Pharmaceutical Imports & Exports Indicators 2006-2014 - Other Healthcare Data - Key Risks To BMI Forecasts Competitive Landscape - Pharmaceutical Sector - Domestic Pharmaceutical Industry - Recent Pharmaceutical Sector Developments - Pharmaceutical Distribution and Retail Company Profiles - Indigenous Pharmaceutical Firms - LaGray Chemical Company - Historical D - DanAdams Pharmaceutical Industry BMI Methodology - How We Generate Our Pharmaceutical Industry Forecasts - Pharmaceuticals Business Environment Ratings - Risk/Reward Ratings Methodology - Ratings Overview - Table: Pharmaceutical Business Environment Indicators - Weighting - Table: Weighting Of Components - Sources About Business Monitor International Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets. BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports. Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports. View more research from Business Monitor International at http://www.fastmr.com/ About Fast Market Research Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156. # # # Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available. End
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number